259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug industry. We also discuss the latest on Sarepta Therapeutics and its gene therapy for Duchenne muscular dystrophy, a turnaround story in the making at the Belgian drug maker Galapagos, and the effort to secure approval for a maternal RSV vaccine.

Episode metadata supplied by the publisher feed · Published May 18, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

0:00 40:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 40 minutes long.

When was this The Readout Loud episode published?

This episode was published on May 18, 2023.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!